Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01452126 · ClinicalTrials.gov registry record · Phase 2
Minimum Effective Concentration of Ropivacaine for Brachial Plexus Block Via the Supraclavicular and Infraclavicular Approach, Femoral Nerve Block, Sciatic Nerve Block Via the Popliteal and Parasacral Approach
A Phase 2 study, sponsored by University of New Mexico.
- Terminated
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
NCT01452126 is a Phase 2 study that was terminated before completion, run by University of New Mexico. The registered enrollment target is 49 participants.
The verdict
NCT01452126, a Phase 2 study, was terminated before completion, sponsored by University of New Mexico.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
Study Summary
This is a dose finding study to identify the minimum effective anesthetic concentration (MEAC) of ropivacaine to produce insensate body parts sufficient for surgery in supraclavicular and infraclavicular approaches to the brachial plexus, parasacral and popliteal approaches to the sciatic nerve, femoral nerve and transversus abdominis plane (TAP) blocks in adults.
Interventions
- DRUG Ropivacaine concentration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2011-06 |
| Est. Completion | 2011-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01452126
The ClinicalTrials.gov registry entry for NCT01452126 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of New Mexico, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ropivacaine concentration is the first listed.
NCT01452126 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01452126 about?
NCT01452126 is a clinical study titled "Minimum Effective Concentration of Ropivacaine for Brachial Plexus Block Via the Supraclavicular and Infraclavicular Approach, Femoral Nerve Block, Sciatic Nerve Block Via the Popliteal and Parasacral Approach". This is a dose finding study to identify the minimum effective anesthetic concentration (MEAC) of ropivacaine to produce insensate body parts sufficient for surgery in supraclavicular and infraclavicular approaches to the brachial plexus, parasacral and popliteal approaches to the sciatic nerve, fem...
What is the current status of trial NCT01452126?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2011-06. Estimated completion is 2011-09.
What interventions are being tested in trial NCT01452126?
The interventions under investigation include: Ropivacaine concentration (DRUG).
Who is sponsoring clinical trial NCT01452126?
This trial is sponsored by University of New Mexico, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.